Monitoring of #human #coronaviruses in #Belgian primary care and #hospitals, 2015–20: a surveillance study (Lancet Microbe, abstract)

[Source: Lancet Microbe, full page: (LINK). Abstract, edited.]

Monitoring of human coronaviruses in Belgian primary care and hospitals, 2015–20: a surveillance study

Natalie Fischer, PhD, Nicolas Dauby, PhD, Nathalie Bossuyt, MD, Marijke Reynders, MD, Michèle Gérard, MD, Patrick Lacor, MD, Siel Daelemans, MD, Bénédicte Lissoir, MD, Xavier Holemans, MD, Koen Magerman, MD, Door Jouck, MD, Marc Bourgeois, MD, Bénédicte Delaere, MD, Sophie Quoilin, MD, Steven Van Gucht, PhD, Isabelle Thomas, PhD, Cyril Barbezange, PhD  †, Lorenzo Subissi, PhD †

Open Access | Published: January 27, 2021 | DOI: https://doi.org/10.1016/S2666-5247(20)30221-4

Summary

Background

Seasonal human coronaviruses (hCoVs) broadly circulate in humans. Their epidemiology and effect on the spread of emerging coronaviruses has been neglected thus far. We aimed to elucidate the epidemiology and burden of disease of seasonal hCoVs OC43, NL63, and 229E in patients in primary care and hospitals in Belgium between 2015 and 2020.

Methods

We retrospectively analysed data from the national influenza surveillance networks in Belgium during the winter seasons of 2015–20. Respiratory specimens were collected through the severe acute respiratory infection (SARI) and the influenza-like illness networks from patients with acute respiratory illness with onset within the previous 10 days, with measured or reported fever of 38°C or greater, cough, or dyspnoea; and for patients admitted to hospital for at least one night. Potential risk factors were recorded and patients who were admitted to hospital were followed up for the occurrence of complications or death for the length of their hospital stay. All samples were analysed by multiplex quantitative RT-PCRs for respiratory viruses, including seasonal hCoVs OC43, NL63, and 229E. We estimated the prevalence and incidence of seasonal hCoV infection, with or without co-infection with other respiratory viruses. We evaluated the association between co-infections and potential risk factors with complications or death in patients admitted to hospital with seasonal hCoV infections by age group. Samples received from week 8, 2020, were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Findings

2573 primary care and 6494 hospital samples were included in the study. 161 (6·3%) of 2573 patients in primary care and 371 (5·7%) of 6494 patients admitted to hospital were infected with a seasonal hCoV. OC43 was the seasonal hCoV with the highest prevalence across age groups and highest incidence in children admitted to hospital who were younger than 5 years (incidence 9·0 [95% CI 7·2–11·2] per 100 000 person-months) and adults older than 65 years (2·6 [2·1–3·2] per 100 000 person-months). Among 262 patients admitted to hospital with seasonal hCoV infection and with complete information on potential risk factors, 66 (73·3%) of 90 patients who had complications or died also had at least one potential risk factor (p=0·0064). Complications in children younger than 5 years were associated with co-infection (24 [36·4%] of 66; p=0·017), and in teenagers and adults (≥15 years), more complications arose in patients with a single hCoV infection (49 [45·0%] of 109; p=0·0097). In early 2020, the Belgian SARI surveillance detected the first SARS-CoV-2-positive sample concomitantly with the first confirmed COVID-19 case with no travel history to China.

Interpretation

The main burden of severe seasonal hCoV infection lies with children younger than 5 years with co-infections and adults aged 65 years and older with pre-existing comorbidities. These age and patient groups should be targeted for enhanced observation when in medical care and in possible future vaccination strategies, and co-infections in children younger than 5 years should be considered during diagnosis and treatment. Our findings support the use of national influenza surveillance systems for seasonal hCoV monitoring and early detection, and monitoring of emerging coronaviruses such as SARS-CoV-2.

Funding

Belgian Federal Public Service Health, Food Chain Safety, and Environment; Belgian National Insurance Health Care (Institut national d’assurance maladie-invalidité/Rijksinstituut voor ziekte-en invaliditeitsverzekering); and Regional Health Authorities (Flanders Agentschap zorg en gezondheid, Brussels Commission communautaire commune, Wallonia Agence pour une vie de qualité).

Keywords: Coronavirus; SARS-CoV-2; SARI; Belgium.

——

#EVD68 – ASSOCIATED #RESPIRATORY #INFECTION IN SOUTHERN #BRAZIL, 2018 – A POPULATION-BASED LABORATORY SURVEILLANCE (J Clin Virol., abstract)

[Source: Journal of Clinical Virology, full page: (LINK). Abstract, edited.]

Journal of Clinical Virology | Available online 11 June 2020, 104503 | In Press, Journal Pre-proof | Short communication

ENTEROVIRUS D68-ASSOCIATED RESPIRATORY INFECTION IN SOUTHERN BRAZIL, 2018 – A POPULATION-BASED LABORATORY SURVEILLANCE

SM Raboni a, HI Giamberardino b, MC Debur c, JS Santos a

a Virology Laboratory, Universidade Federal do Paraná, Curitiba, Brazil;  b Epidemiology Division, Hospital Pequeno Príncipe, Curitiba, Brazil; c Public Health Laboratory, Secretaria de Saúde do Estado do Paraná, Curitiba, Brazil

Received 4 May 2020, Revised 29 May 2020, Accepted 8 June 2020, Available online 11 June 2020.

DOI: https://doi.org/10.1016/j.jcv.2020.104503

 

Highlights

  • Patients with SARI or ILI notified during epidemiological surveillance are investigated to detect respiratory virus.
  • Enteroviruses were detected in 69/6,535 (1%), being 39/69 (56.5%) of SARI, and 30/69 (43.5%) of ILI cases.
  • EV-D68 was detected in the 36 samples previously identified as EV/RV co-detection.
  • This finding settles the sustained circulation of EV-D68 in southern Brazil.

 

Abstract

Enterovirus D68 (EV-D68) strain was confirmed in 36/69 – 52.2% of enterovirus-positive samples collected through surveillance networks for severe acute respiratory infections (SARI) and influenza-like illness (ILI) in southern Brazil in 2018. This finding settles the sustained circulation of EV-D68 in southern Brazil.

Keywords: Enterovirus; EV-D68; SARI; Brazil.

——

#COVID19 and Hospitalizations for #SARI in #Brazil: A #Comparison Up to the 12th Epidemiological Week of 2020 (Cad Saude Publica, abstract)

[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]

 Cad Saude Publica. 2020 Apr 22;36(4):e00070120. doi: 10.1590/0102-311X00070120. eCollection 2020.

COVID-19 and Hospitalizations for SARI in Brazil: A Comparison Up to the 12th Epidemiological Week of 2020

[Article in English, Portuguese]

Leonardo Soares Bastos 1 2, Roberta Pereira Niquini 3, Raquel Martins Lana 1, Daniel A M Villela 1, Oswaldo G Cruz 1, Flávio C Coelho 4, Claudia T Codeço 1, Marcelo F C Gomes 1

Affiliations: 1 Programa de Computação Científica, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil. 2 Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, U.K. 3 Instituto Federal de Educação, Ciência e Tecnologia do Rio de Janeiro, Rio de Janeiro, Brasil. 4 Escola de Matemática Aplicada, Fundação Getúlio Vargas, Rio de Janeiro, Brasil.

PMID: 32321075 DOI: 10.1590/0102-311X00070120

 

Abstract in English , Portuguese , Spanish

Surveillance of the severe acute respiratory illness (SARI) in Brazil aims to characterize the circulation of the Influenza A and B viruses in hospitalized cases and deaths, having been expanded in 2012 to include other respiratory viruses. COVID-19 was detected in Brazil for the time in the 9th epidemiological week of 2020, and the test for the SARS-CoV-2 virus was included in the surveillance protocol starting in the 12th epidemiological week. This study’s objective was to investigate the pattern of hospitalizations for SARI in Brazil since the entry of SARS-CoV-2, comparing the temporal and age profiles and laboratory results to the years 2010 through 2019. In 2020, hospitalizations for SARI, compiled from the date of the first confirmed case of COVID-19 up to the 12th week, exceeded the numbers observed during the same period in each of the previous 10 years. The age bracket over 60 years was the most heavily affected, at higher than historical levels. There was a considerable increase in negative laboratory tests, suggesting circulation of a different virus from those already present in the panel. We concluded that the increase in hospitalizations for SARI, the lack of specific information on the etiological agent, and the predominance of cases among the elderly during the same period in which there was an increase in the number of new cases of COVID-19 are all consistent with the hypothesis that severe cases of COVID-19 are already being detected by SARI surveillance, placing an overload on the health system. The inclusion of testing for SARS-CoV-2 in the SARI surveillance protocol and the test’s effective nationwide deployment are extremely important for monitoring the evolution of severe COVID-19 cases in Brazil.

Keywords: SARS-CoV-2; COVID-19; Brazil; SARI.

—–

Conventional #Respiratory #Support #Therapy for #SARI: #Clinical Indications and #Nosocomial #IPC (Zhonghua Jie He He Hu Xi Za Zhi, abstract)

[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]

Zhonghua Jie He He Hu Xi Za Zhi, 43 (0), E015 2020 Feb 16 [Online ahead of print]

Conventional Respiratory Support Therapy for Severe Acute Respiratory Infections (SARI): Clinical Indications and Nosocomial Infection Prevention and Control

[Article in Chinese]

Critical care committee of Chinese Association of Chest Physician, Respiratory and critical care group of Chinese Thoracic Society, Respiratory care group of Chinese Thoracic Society

PMID: 32061199 DOI: 10.3760/cma.j.issn.1001-0939.2020.0015

 

Abstract in English , Chinese

Severe acute respiratory infection (SARI) diseases (such as SARS, MERS, pH1N1) can rapidly progress to acute respiratory failure with high lethality. The outbreak of a novel coronavirus infection can lead to 15% ~ 30% patients developing into acute respiratory distress syndrome (ARDS). Respiratory support is the most important therapy for SARI patients with respiratory failure. However, respiratory support is a high skilled technology, which means inappropriate application may bring related complications and cross infection of SARI pathogens among medical staff and non-medical personnel in hospital. Therefore, it is meaningful to established a standardized indication of respiratory support and to prevent related nosocomial transmission in SARI patients.

Keywords: High Flow Nasal Cannula; Noninvasive positive pressure ventilation; Novel Coronavirus Pneumonia; Respiratory support; Severe Acute Respiratory Infections.

Keywords: SARS-CoV-2; COVID-19; SARI; ARDS.

—–

#Clinical #Features of Fatal Pandemic #Influenza A/ #H1N1 #Infection Complicated by Invasive #Pulmonary #Fungal Infection (Mycopathologia, abstract)

[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]

Mycopathologia. 2019 Dec 27. doi: 10.1007/s11046-019-00421-z. [Epub ahead of print]

Clinical Features of Fatal Pandemic Influenza A/H1N1 Infection Complicated by Invasive Pulmonary Fungal Infection.

Yu Z1, Gu Q1, Zhang B1, Chen X1, Tang J1, Hou Y1, Yu W2.

Author information: 1 Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, Nanjing, China. 2 Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, Nanjing, China. yudrnj@163.com.

 

Abstract

BACKGROUND:

Severe pneumonia caused by influenza virus infection can be secondary to invasive pulmonary fungal (IPF) infection.

OBJECTIVES:

This study aimed to summarize the incidence of IPF infection secondary to influenza virus infection and further explore its etiologic mechanism and high-risk factors.

METHODS:

All adult patients with confirmed influenza A (H1N1) virus infection admitted to the intensive care units (ICUs) of Nanjing Drum Hospital from November 2017 to March 2018 were retrospectively selected. The differences in baseline factors, risk factors, immune function and outcome parameters were studied between patients with and without IPF.

RESULTS:

Of the 19 critically ill patients with H1N1 infection, 11 (57.9%) developed IPF infection after 7 days of ICU admission. Two patients had proven and nine probable IPF infection. A difference in human leukocyte antigen-DR isotype (△HLA-DR; day 7-day 1) was found between the two groups. △HLA-DR (day 7-day 1) was higher in patients with no IPF infection than in those with IPF infection [(14.52 ± 14.21)% vs ( - 11.74 ± 20.22)%, P = 0.019]. The decline in HLA-DR indicated impaired immune function secondary to fungal infection in patients with H1N1 infection.

CONCLUSIONS:

IPF infection was diagnosed in 57.9% of critically ill patients with H1N1 virus infection after a median of 7 days following ICU admission. A continuous decline in immune function could lead to the development of IPF infections. Dynamic monitoring of immune function may help in the early detection of IPF infection.

KEYWORDS: H1N1; Human leukocyte antigen-DR isotype (HLA-DR); Invasive pulmonary fungal infection; Severe pneumonia

PMID: 31883036 DOI: 10.1007/s11046-019-00421-z

Keywords: Seasonal Influenza; Fungal infections; Pneumonia; SARI.

——-

Comparative effectiveness of combined #favipiravir and #oseltamivir #therapy versus oseltamivir monotherapy in critically ill patients with #influenza virus infection (J Infect Dis., abstract)

[Source: Journal of Infectious Diseases, full page: (LINK). Abstract, edited.]

Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection

Yeming Wang, Guohui Fan, Alex Salam, Peter Horby, Frederick G Hayden, Cheng Chen, Jianguang Pan, Jing Zheng, Binghuai Lu, Liping Guo, Chen Wang, Bin Cao, CAP-China Network

The Journal of Infectious Diseases, jiz656, https://doi.org/10.1093/infdis/jiz656

Published: 11 December 2019

 

Abstract

Background

A synergistic effect of combination therapy with favipiravir and oseltamivir has been reported in pre-clinical models of influenza. However, no data are available on the clinical effectiveness of combination therapy in severe influenza.

Methods

Data from two separate prospective studies of influenza adults were used to compare outcomes between combination and oseltamivir monotherapy. Outcomes includes rate of clinical improvement, defined as a decrease of 2 categories on a 7-category ordinal scale, and viral RNA detectability over time. Sub-hazard ratio (sHR) was estimated by Fine and Gray model for competing risks.

Results

In total, 40 patients were treated with combination therapy and 128 with oseltamivir alone. Clinical improvement on Day 14 occurred in the combination group was higher than in monotherapy group (62.5% vs 42.2%, p=0.0247). The adjusted sHR for combination therapy was 2.06 (95%CI: 1.3-3.26). The proportion of undetectable viral RNA at day 10 was higher in the combination group than oseltamivir group (67.5% vs 21.9%, p<0.01). No significant differences were observed in mortality or other outcomes.

Conclusions

Favipiravir and oseltamivir combination therapy may accelerate clinical recovery compared to oseltamivir monotherapy in severe influenza, and this strategy should be formally evaluated in a randomized controlled trial.

Topic: influenza – combined modality therapy – critical illness – orthomyxoviridae – infection – oseltamivir – comparative effectiveness research – favipiravir

Issue Section: Major Article

This content is only available as a PDF.

Keywords: Influenza A; Antivirals; SARI; Oseltamivir; Favipiravir.

——

The Acute #Respiratory #Infection Consortium: A Multi-Site, Multi-Disciplinary #Clinical #Research Network in the #DoD (Mil Med., abstract)

[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]

Mil Med. 2019 Nov 1;184(Supplement_2):44-50. doi: 10.1093/milmed/usz174.

The Acute Respiratory Infection Consortium: A Multi-Site, Multi-Disciplinary Clinical Research Network in the Department of Defense.

Coles C1,2, Millar EV1,2, Burgess T1, Ottolini MG3.

Author information: 1 Infectious Disease Clinical Research Program, Preventive Medicine & Biostatistics Department, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814. 2 Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., 6720A Rockledge Drive, Bethesda, MD 20817. 3 Preventive Medicine & Biostatistics Department, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814.

 

Abstract

INTRODUCTION:

Acute respiratory infections (ARI) result in substantial annual morbidity among military personnel and decrease operational readiness. Herein, we summarize the research efforts of the Infectious Disease Clinical Research Program (IDCRP) related to ARIs.

METHODS:

The ARI Research Area of the IDCRP was established in response to the 2009 emergence of pandemic influenza A/H1N1. That year, IDCRP investigators deployed the ARI Consortium Natural History Study (ARIC NHS), a multi-centered, longitudinal observational study to assess etiology, epidemiology, and clinical characteristics of influenza-like illness (ILI) and severe acute respiratory infections (SARI) in the U.S. military. The success of this initial effort spurred implementation of several new initiatives. These include the FluPlasma trial, designed to evaluate the efficacy of hyperimmune anti-influenza plasma for the treatment of severe influenza; the self-administered live-attenuated influenza vaccine (SNIF) trial, which assessed the immunogenicity and acceptance of a self-administered live-attenuated influenza vaccine in military personnel; the Study to Address Threats of ARI in Congregate Military Populations (ATARI), a prospective study of ILI transmission, etiology and epidemiology in recruits; and the Flu Breath Test (FBT) study, a preliminary study of exhaled volatile organic compounds (VOC) in influenza patients. In addition, the InFLUenza Patient-Reported Outcome (FLU-PRO) survey, a daily diary to measure influenza symptoms during clinical trials, was developed. Lastly, the Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED) study, a two-year randomized trial designed to compare the effectiveness of the three types of licensed vaccines, launched in Fall 2018.

RESULTS:

The on-going ARIC NHS has enrolled over 2000 ILI and SARI cases since its inception, providing data on burden and clinical manifestations of ARI in military personnel and their families. The FluPlasma 2 trial concluded subject enrollment in 2018. Preliminary results from ATARI study show a high frequency of respiratory viruses circulating during the first two weeks of recruit training. Based on assessment of FLU-PRO responses, which were found to be reliable and reproducible, the survey may be a useful tool in clinical trials and epidemiological studies. The Flu Breath Study will complete enrollment in 2019. Findings from PAIVED are intended to provide evidence needed for assessing influenza vaccination policy in the military.

CONCLUSIONS:

The ARI burden in the armed services remains significant every year and the threat is dynamic given emergent and evolving threats, such as influenzas. With strong successes to date, future initiatives of the ARI Research Area will focus on interventional studies, ARI transmission dynamics in congregate military settings, and determinants of risk of pandemic influenza and other emergent respiratory viruses.

© Association of Military Surgeons of the United States 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

KEYWORDS: acute respiratory infections; influenza; influenza-like illness; military health

PMID: 31778194 DOI: 10.1093/milmed/usz174

Keywords: Seasonal Influenza; Pandemic Influenza; Military; Serotherapy; Vaccines; USA; SARI.

——

Post- #pandemic #influenza A/ #H1N1pdm09 is associated with more severe #outcomes than A/ #H3N2 and other #respiratory viruses in adult hospitalisations (Epidemiol Infect., abstract)

[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]

Epidemiol Infect. 2019 Nov 28;147:e310. doi: 10.1017/S095026881900195X.

Post-pandemic influenza A/H1N1pdm09 is associated with more severe outcomes than A/H3N2 and other respiratory viruses in adult hospitalisations.

Minney-Smith CA1,2, Selvey LA3, Levy A2,4, Smith DW2,4.

Author information: 1 School of Public Health, Curtin University, Bentley, Western Australia, Australia. 2 PathWest Laboratory Medicine WA, Nedlands, Western Australia, Australia. 3 School of Public Health, The University of Queensland, Herston, Queensland, Australia. 4 School of Biomedical Sciences, University of Western Australia, Nedlands, Australia.

 

Abstract

This study compares the frequency and severity of influenza A/H1N1pdm09 (A/H1), influenza A/H3N2 (A/H3) and other respiratory virus infections in hospitalised patients. Data from 17 332 adult hospitalised patients admitted to Sir Charles Gairdner Hospital, Perth, Western Australia, with a respiratory illness between 2012 and 2015 were linked with data containing reverse transcription polymerase chain reaction results for respiratory viruses including A/H1, A/H3, influenza B, human metapneumovirus, respiratory syncytial virus and parainfluenza. Of these, 1753 (10.1%) had test results. Multivariable regression analyses were conducted to compare the viruses for clinical outcomes including ICU admission, ventilation, pneumonia, length of stay and death. Patients with A/H1 were more likely to experience severe outcomes such as ICU admission (OR 2.5, 95% CI 1.2-5.5, P = 0.016), pneumonia (OR 3.0, 95% CI 1.6-5.7, P < 0.001) and lower risk of discharge from hospital (indicating longer lengths of hospitalisation; HR 0.64 95% CI 0.47-0.88, P = 0.005), than patients with A/H3. Patients with a non-influenza respiratory virus were less likely to experience severe clinical outcomes than patients with A/H1, however, had similar likelihood when compared to patients with A/H3. Patients hospitalised with A/H1 had higher odds of severe outcomes than patients with A/H3 or other respiratory viruses. Knowledge of circulating influenza strains is important for healthcare preparedness.

KEYWORDS: A/H1N1pdm09; A/H3N2; hospitalisation; influenza; respiratory viruses

PMID: 31775940 DOI: 10.1017/S095026881900195X

Keywords: Seasonal Influenza; H1N1pdm09; H3N2; SARI; Pneumonia; Intensive Care.

——

#Risk of Severe #Influenza among #Adults with #Chronic Medical #Conditions (J Infect Dis., abstract)

[Source: Journal of Infectious Diseases, full page: (LINK). Abstract, edited.]

Risk of Severe Influenza among Adults with Chronic Medical Conditions

Tiffany A Walker, MD, Ben Waite, MSc, Mark G Thompson, PhD, Colin McArthur, MBChB, Conroy Wong, MBChB, Michael G Baker, MBChB, Tim Wood, MSc, Jennifer Haubrock, Sally Roberts, MBChB, Diane K Gross, PhD, Q Sue Huang, PhD, E Claire Newbern, PhD

The Journal of Infectious Diseases, jiz570, https://doi.org/10.1093/infdis/jiz570

Published: 04 November 2019

 

Abstract

Background

Severe influenza illness is presumed more common in adults with chronic medical conditions (CMC), but evidence is sparse and often combined into broad CMC categories.

Methods

Residents (aged 18–80 years) of Central and South Auckland hospitalized for WHO-defined severe acute respiratory illness (SARI) (2012–2015) underwent influenza virus PCR testing. CMC statuses for Auckland residents were modelled using hospitalization ICD-10 codes, pharmaceutical claims, and laboratory results. Population-level influenza rates in adults with congestive heart failure (CHF), coronary artery disease (CAD), cerebrovascular accidents (CVA), chronic obstructive pulmonary disease (COPD), asthma, diabetes mellitus (DM), and end-stage renal disease (ESRD) were calculated by Poisson regression stratified by age and adjusted for ethnicity.

Results

Among 891,276 adults, 2,435 influenza-associated SARI hospitalizations occurred. Rates were significantly higher in those with CMCs compared with those without the respective CMC except older adults with DM or those aged <65 years with CVA. The largest effects occurred with CHF (Incidence Rate Ratio [IRR] range: 4.84–13.4 across age strata), ESRD (IRR range: 3.30–9.02), CAD (IRR range= 2.77–10.7), and COPD (IRR range: 5.89–8.78) and tapered with age.

Conclusions

Our findings support the increased risk of severe, laboratory-confirmed influenza disease among adults with specific CMCs compared those without these conditions.

influenza hospitalizations, influenza incidence, influenza risk, chronic medical conditions

Topic: influenza – chronic obstructive airway disease – cerebrovascular accident – kidney failure, chronic – congestive heart failure – adult

Issue Section: Major Article

This content is only available as a PDF.

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Keywords: Seasonal Influenza; SARI.

—–

Seasonal #Influenza and #Avian Influenza A(#H5N1) Virus #Surveillance among Inpatients and Outpatients, East #Jakarta, #Indonesia, 2011–2014 (Emerg Infect Dis., abstract)

[Source: US Centers for Disease Control and Prevention (CDC), Emerging Infectious Diseases Journal, full page: (LINK). Abstract, edited.]

Volume 25, Number 11—November 2019 / Research

Seasonal Influenza and Avian Influenza A(H5N1) Virus Surveillance among Inpatients and Outpatients, East Jakarta, Indonesia, 2011–2014

Kathryn E. Lafond1  , Catharina Y. Praptiningsih1, Amalya Mangiri, Misriyah Syarif, Romadona Triada, Ester Mulyadi, Chita Septiawati, Vivi Setiawaty, Gina Samaan, Aaron D. Storms, Timothy M. Uyeki, and A. Danielle Iuliano

Author affiliations: University of Tampere, Tampere, Finland (K.E. Lafond); US Centers for Disease Control and Prevention, Atlanta, Georgia, USA (K.E. Lafond, A.D. Storms, T.M. Uyeki, A.D. Iuliano); US Centers for Disease Control and Prevention, Jakarta, Indonesia (C.Y. Praptiningsih, A. Mangiri, E. Mulyadi); Ministry of Health, Jakarta (M. Syarif, R. Triada, C. Septiawati, V. Setiawaty); Australian National University, Canberra, Capital Territory, Australia (G. Samaan)

 

Abstract

During October 2011–September 2014, we screened respiratory specimens for seasonal and avian influenza A(H5N1) virus infections among outpatients with influenza-like illness and inpatients with severe acute respiratory infection (SARI) in East Jakarta, an Indonesia district with high incidence of H5N1 virus infection among poultry. In total, 31% (1,875/6,008) of influenza-like illness case-patients and 15% (571/3,811) of SARI case-patients tested positive for influenza virus. Influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B virus infections were detected in all 3 years, and the epidemic season extended from November through May. Although 28% (2,810/10,135) of case-patients reported exposure to poultry, only 1 SARI case-patient with an H5N1 virus infection was detected. Therefore, targeted screening among case-patients with high-risk poultry exposures (e.g., a recent visit to a live bird market or close proximity to sick or dead poultry) may be a more efficient routine surveillance strategy for H5N1 virus in these types of settings.

Keywords: Seasonal Influenza; Avian Influenza; H1N1pdm09; H3N2; H5N1; SARI; Indonesia.

——